Bristol Myers Squibb (BMY) Stock Price, News & Analysis

Company Overview

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions. Bristol Myers Squibb focuses on innovative medicines, including biologic and small-molecule therapies, and invests in research across areas such as oncology, hematology, immunology, cardiovascular disease and neuroscience.

Bristol Myers Squibb traces its history to the formation of Bristol-Myers in 1881 and the founding of E.R. Squibb & Sons in 1858. The businesses merged in 1989 to create Bristol-Myers Squibb. More recent expansion has included the acquisition of Celgene in 2019, which strengthened the company’s presence in hematology and oncology, and Karuna Therapeutics in 2024, which added a neuroscience medicine to its portfolio. Christopher Boerner serves as the company’s chief executive officer.

Key Stats

• Today's Range: $64.39 to $65.89
• 50-Day Range: $56.46 to $68.06
• 52-Week Range: $42.52 to $68.64
• Volume: 9.52 million shs
• Average Volume: 7.64 million shs
• Market Capitalization: $132.02 billion
• P/E Ratio: 14.24
• Dividend Yield: 3.90%
• Price Target: $66.06
• Consensus Rating: Moderate Buy

Bristol Myers Squibb Stock Analysis - MarketRank™

Bristol Myers Squibb scored higher than 94% of companies evaluated by MarketBeat, and ranked 24th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bristol Myers Squibb has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 13 buy ratings, 10 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Bristol Myers Squibb has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: -7.34%

Earnings Growth

Earnings for Bristol Myers Squibb are expected to decrease by -7.34% in the coming year, from $6.95 to $6.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bristol Myers Squibb is 14.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bristol Myers Squibb is 14.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.68.

Price to Earnings Growth Ratio

Bristol Myers Squibb has a PEG Ratio of 0.32. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Bristol Myers Squibb has a P/B Ratio of 7.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.25% of the float of Bristol Myers Squibb has been sold short.

Short Interest Ratio / Days to Cover

Bristol Myers Squibb has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bristol Myers Squibb has recently decreased by 12.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 5.0 / 5
• Dividend Strength: Strong

Dividend Leadership

Bristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 3.77%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Bristol Myers Squibb has been increasing its dividend for 17 years.

Dividend Coverage

The dividend payout ratio of Bristol Myers Squibb is 55.51%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 39.13% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.92

News Sentiment

Bristol Myers Squibb has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 40 news articles for Bristol Myers Squibb this week, compared to 11 articles on an average week.

Search Interest

Only 49 people have searched for BMY on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

38 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 46% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,750.00 in company stock.

Percentage Held by Insiders

0.05% of the stock of Bristol Myers Squibb is held by insiders.

Percentage Held by Institutions

76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 8/3 Dividend: 7/02/2026
• Ex-Dividend for 8/3 Dividend: 7/02/2026
• Last Earnings: 7/30/2026
• Dividend Payable: 8/03/2026
• Today: 9/09/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:BMY
• CIK: 14272
• Web: www.bms.com
• Phone: (609) 252-4621
• Fax: 212-546-4020
• Employees: 32,500
• Year Founded: 1887

Price Target and Rating

• Average Price Target for Bristol Myers Squibb: $66.06
• High Price Target: $75.00
• Low Price Target: $40.00
• Potential Upside/Downside: +2.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.54
• Trailing P/E Ratio: 14.24
• Forward P/E Ratio: 9.30
• P/E Growth: 0.32
• Net Income: $7.05 billion
• Net Margins: 18.87%
• Pretax Margin: 24.21%
• Return on Equity: 66.90%
• Return on Assets: 14.74%

Debt

• Debt-to-Equity Ratio: 1.89
• Current Ratio: 1.53
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $49.19 billion
• Price / Sales: 2.68
• Cash Flow: $7.86 per share
• Price / Cash Flow: 8.22
• Book Value: $9.09 per share
• Price / Book: 7.11

Miscellaneous

• Outstanding Shares: 2,042,715,000
• Free Float: 2,041,694,000
• Market Cap: $132.02 billion
• Optionable: Optionable
• Beta: 0.23